Uncovering the facts, Holding government accountable.
Published:February 2, 2022
FOIA to FDA for Communications Sent Between FDA Officials and External Entities Regarding Aduhelm
FOIA request to the U.S. Food and Drug Administration seeking communications sent by senior FDA officials to external entities regarding Aduhelm (aducanumab), an Alzheimer’s drug produced by Biogen. HHS-FDA-22-0115
Select a tag below to see a full list of related documents